Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency

C. Daniel Mullins, Lisa Blatt, Junling Wang

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The use of intermittent augmentation therapy for patients with α1-antitrypsin deficiency assists in slowing disease progression and may, as a result, reduce the likelihood of hospitalization and significant clinical events. There are significant cost and access issues related to current therapy management, since currently marked augmentation therapy is expensive and there have been periodic shortages. The high cost, access and reimbursement concerns have prompted questions about the potential pharmacoeconomic advantages of future treatments. In this review, we provide an overview of published research findings concerning the effectiveness of current therapy, reimbursement and cost issues and potential future advances in treatment for α1-antitrypsin deficiency.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume2
Issue number3
DOIs
StatePublished - Jul 2 2002
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Costs and Cost Analysis
Therapeutics
Disease Progression
Hospitalization
Research

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Pharmacology (medical)

Cite this

Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency. / Mullins, C. Daniel; Blatt, Lisa; Wang, Junling.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 2, No. 3, 02.07.2002, p. 243-249.

Research output: Contribution to journalReview article

@article{1db996206d384b0b8d61bc8d3f02a7d4,
title = "Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency",
abstract = "The use of intermittent augmentation therapy for patients with α1-antitrypsin deficiency assists in slowing disease progression and may, as a result, reduce the likelihood of hospitalization and significant clinical events. There are significant cost and access issues related to current therapy management, since currently marked augmentation therapy is expensive and there have been periodic shortages. The high cost, access and reimbursement concerns have prompted questions about the potential pharmacoeconomic advantages of future treatments. In this review, we provide an overview of published research findings concerning the effectiveness of current therapy, reimbursement and cost issues and potential future advances in treatment for α1-antitrypsin deficiency.",
author = "Mullins, {C. Daniel} and Lisa Blatt and Junling Wang",
year = "2002",
month = "7",
day = "2",
doi = "10.1586/14737167.2.3.243",
language = "English (US)",
volume = "2",
pages = "243--249",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency

AU - Mullins, C. Daniel

AU - Blatt, Lisa

AU - Wang, Junling

PY - 2002/7/2

Y1 - 2002/7/2

N2 - The use of intermittent augmentation therapy for patients with α1-antitrypsin deficiency assists in slowing disease progression and may, as a result, reduce the likelihood of hospitalization and significant clinical events. There are significant cost and access issues related to current therapy management, since currently marked augmentation therapy is expensive and there have been periodic shortages. The high cost, access and reimbursement concerns have prompted questions about the potential pharmacoeconomic advantages of future treatments. In this review, we provide an overview of published research findings concerning the effectiveness of current therapy, reimbursement and cost issues and potential future advances in treatment for α1-antitrypsin deficiency.

AB - The use of intermittent augmentation therapy for patients with α1-antitrypsin deficiency assists in slowing disease progression and may, as a result, reduce the likelihood of hospitalization and significant clinical events. There are significant cost and access issues related to current therapy management, since currently marked augmentation therapy is expensive and there have been periodic shortages. The high cost, access and reimbursement concerns have prompted questions about the potential pharmacoeconomic advantages of future treatments. In this review, we provide an overview of published research findings concerning the effectiveness of current therapy, reimbursement and cost issues and potential future advances in treatment for α1-antitrypsin deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0036078175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036078175&partnerID=8YFLogxK

U2 - 10.1586/14737167.2.3.243

DO - 10.1586/14737167.2.3.243

M3 - Review article

VL - 2

SP - 243

EP - 249

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 3

ER -